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Abstract
Integrin αvβ3 receptors are expressed on activated endothelial cells during neovascularization to
maintain tumor growth. Many radiolabeled probes utilize the tight and specific association
between the arginine-glycine-aspartatic acid (RGD) peptide and integrin αvβ3, but one main
obstacle for any clinical application of these probes is the laborious multistep radiosynthesis
of 18F. In this study, the dimeric RGD peptide, E-[c(RGDfK)]2, was conjugated with NODAGA
and radiolabeled with 18F in a simple one-pot process with a radiolabeling yield of 20%; the whole
process lasting only 45 min. NODAGA-E-[c(RGDfK)]2 labeled with 18F at a specific activity of
1.8 MBq/nmol and a radiochemical purity of 100% could be achieved. Log P value of 18F-labeled
NODAGA-E-[c(RGDfK)]2 was −4.26 ± 0.02. In biodistribution studies, 18F-NODAGA-E-
[c(RGDfK)]2 cleared rapidly from the blood with 0.03 ± 0.01 %ID/g in the blood at 2 h p.i.,
mainly via the kidneys and showed good in vivo stability. Tumor uptake of 18F-NODAGA-E-
[c(RGDfK)]2 (3.44 ± 0.20 %ID/g, 2 h p.i.) was significantly lower than that of reference
compounds 68Ga-labeled NODAGA-E-[c(RGDfK)]2 (6.26 ± 0.76 %ID/g; P <0.001) and 111In-
labeled NODAGA-E-[c(RGDfK)]2 (4.99 ± 0.64 %ID/g; P < 0.01). Co-injection of an excess of
unlabeled NODAGA-E-[c(RGDfK)]2 along with 18F-NODAGA-E-[c(RGDfK)]2 resulted in
significantly reduced radioactivity concentrations in the tumor (0.85 ± 0.13 %ID/g). The αvβ3
integrin-expressing SK-RC-52 tumor could be successfully visualized by microPET with 18F-
labeled NODAGA-E-[c(RGDfK)]2. In conclusion, NODAGA-E-[c(RGDfK)]2 could be labeled
rapidly with 18F using a direct aqueous, one-pot method and it accumulated specifically in αvβ3
integrin-expressing SK-RC-52 tumors, allowing for visualization by microPET.
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1. INTRODUCTION
Integrin αvβ3 is overexpressed on activated endothelial cells during tumor-induced
angiogenesis, but is absent on quiescent endothelial cells. Ruoslahti and co-workers found
that this integrin interacts with the arginine–glycine–aspartic acid (RGD) amino acid
sequence present on extracellular matrix proteins, such as vitronectin, fibrinogen and
laminin (1). Based on the RGD peptide sequence, series of small cyclic peptides, showing
high and specific affinity for the αvβ3 integrin, have been developed (2).
In the last few years, imaging of angiogenic processes using positron emission tomography
(PET) or single photon emission computed tomography (SPECT) with radiolabeled RGD
peptides has attracted considerable interest. These tracers have the potential to select patients
who might benefit from treatment with antiangiogenic drugs as well as to monitor the
therapeutic efficacy of integrin αvβ3-targeted drugs.
The glycosylated cyclo(RGDfK) analog [18F]galacto-RGD is of the αvβ3 integrin ligands
the most intensely evaluated and studied in cancer patients (3–5). Recently, another 18F-
labeled RGD peptide, 18F-AH111585, has also been tested in preclinical studies and clinical
trials (6–8). Both tracers showed good pharmacokinetics and receptor-specific uptake,
allowing non-invasive imaging of αvβ3 integrin expression. However, the synthesis of these
tracers is complex and time-consuming with moderate yield, which hampers routine use in
the clinical setting.
18F is the most widely used radionuclide in PET and has excellent characteristics for
peptide-based imaging, namely a half-life of 110 min that matches the pharmacokinetics of
most peptides, and the low positron energy of 635 keV results in short ranges in tissue and
excellent preclinical imaging resolution (<2 mm) (9).
For radiofluorination of RGD peptides, a wide range of methods has been investigated.
Chemoselective oxime formation allows high-yield two-step radiosynthesis of 18F-labeled
peptides via conjugation of 18F-labeled aldehydes (e.g. 4-[18F]fluorobenzaldehyde) with an
aminooxy functionality in the peptide (10). However, using 4-[18F]fluorobenzaldehyde as
the prosthetic group, invariably increased ligand lipophilicity, which often leads to
unfavorable characteristics in vivo. It has since been shown that carbohydration is a
powerful method to reduce lipophilicity of small radiolabeled peptides, resulting in
improved pharmacokinetics of the radioligand (11–14). Recently, the direct conjugation of
[18F]FDG as a strategy for simultaneous carbohydration and labeling of a RGD peptide was
investigated and resulted in good pharmacokinetics (15,16). However, this approach requires
the use of carrier-free 18F-FDG, necessitating reversed phase high-performance liquid
chromatography (RP-HPLC) purification of 18F-FDG before conjugation with the
functionalized peptide, further increasing the length of time of preparation.
The Huisgen 1,3-dipolar cycloaddition reaction for radiofluorination of the dimeric RGD
peptide E[c(RGDyK)] was explored and reported by Li and co-workers (17). Although,
click-labeled 18F-FPTA-RGD2 could be obtained with 27% non-decay-corrected labeling
yield and exhibited favorable in vivo pharmacokinetics, this method requires azeotropic
drying of the fluoride, resulting in a time-consuming multistep procedure. In addition,
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new 18F-labeling strategies based on fluorine-silicon (18–24), fluorine-boron (25), and
fluorine-phosphorus (26) have been developed.
In contrast to these laborious radiofluorination methods, McBride et al. developed a direct
aqueous 18F-labeling method wherein 18F is first attached to Al3+. The Al18F2+ is then
bound to a chelator attached to a peptide, forming a stable Al18F-chelate peptide complex in
an efficient 1-pot process (27).
Here, we describe the 18F-labeling of 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid
(NODAGA)-E-[c(RGDfK)]2, using this new Al18F labeling method. The tumor targeting
characteristics of 18F-NODAGA-E-[c(RGDfK)]2 are compared to those of 68Ga- and 111In-
labeled NODAGA-E-[c(RGDfK)]2 both in vitro and in vivo.
2. RESULTS AND DISCUSSION
2.1. Radiolabeling
Al18F-labeled NODAGA-E-[c(RGDfK)]2 was obtained with an overall labeling efficiency
of 20%. A radiochemical purity of >98% was obtained after solid phase extraction on a
hydrophilic-lipophilic balance (HLB) cartridge (Figure 1A). NODAGA-E-[c(RGDfK)]2 was
labeled with 68Ga and 111In with a labeling efficiency of 82% and 91% respectively. HLB
cartridge purification of these increased the radiochemical purity to 85% and 95%
respectively (Figures 1B–C). Specific activities for Al18F-, 68Ga- and 111In-NODAGA-E-
[c(RGDfK)]2 were 1.8 MBq/nmol, 5.5 MBq/nmol and 2.2 MBq/nmol respectively. For
SPECT imaging a higher specific activity was used and 111In-NODAGA-E-[c(RGDfK)]2
was prepared with a specific activity of 40 MBq/nmol.
2.2. Octanol/Water partition coefficient
The lipophilicity of the Al18F-, 68Ga- and 111In-labeled NODAGA-E-[c(RGDfK)]2 was
determined using the octanol-water partition coefficients. The Log Poctanol/PBS values of the
lipophilic radiolabeled dimeric RGD peptides are given in Table 1.
2.3. Competitive Binding Assay
The affinity of NODAGA-E-[c(RGDfK)]2 and DOTA-E-[c(RGDfK)]2 for integrin αvβ3
were determined in a solid-phase competitive binding assay (Figure 2). Binding of 111In-
labeled DOTA-E-[c(RGDfK)]2 to integrin αvβ3 was displaced by NODAGA-E-
[c(RGDfK)]2 and DOTA-E-[c(RGDfK)]2 in a concentration-dependent manner. The IC50
values were in the sub-nanomolar range (0.043 ± 0.037 and 0.037 ± 0.085 nM, respectively),
indicating equally high binding affinity as well as specific binding of both NODAGA-E-
[c(RGDfK)]2 and DOTA-E-[c(RGDfK)]2 to integrin αvβ3.
2.4. Biodistribution Studies
The results of the biodistribution studies of Al18F-, 68Ga- and 111In-labeled NODAGA-E-
[c(RGDfK)]2 are summarized in Figures 3A–C. Al18F-NODAGA-E-[c(RGDfK)]2 cleared
rapidly from the blood with 0.03 ± 0.01 percentage injected dose/gram (%ID/g) in the blood
at 2 h p.i.. A similarly low blood level at 2 h p.i. was found for 68Ga- and 111In-labeled
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NODAGA-E-[c(RGDfK)]2. Tumor uptake of Al18F-labeled NODAGA-E-[c(RGDfK)]2
(3.44 ± 0.20 %ID/g, 2 h p.i.) was significantly lower than that of 68Ga-labeled NODAGA-E-
[c(RGDfK)]2 (6.26 ± 0.76 %ID/g; P <0.001) or 111In-labeled NODAGA-E-[c(RGDfK)]2
(4.99 ± 0.64 %ID/g; P < 0.01). Coinjection of an excess of unlabeled NODAGA-E-
[c(RGDfK)]2 (100 εg) along with Al18F-labeled NODAGA-E-[c(RGDfK)]2 resulted in a
significantly reduced radioactivity concentration in the tumor (0.85 ± 0.13 %ID/g; P
<0.001), indicating that uptake of the major fraction of radiolabeled NODAGA-E-
[c(RGDfK)]2 preparation in the tumor was integrin αvβ3-,mediated. Uptake of Al18F-
NODAGA-E-[c(RGDfK)]2 in non-target organs like intestine, spleen, stomach and liver was
also reduced in the presence of an excess of non-labeled RGD peptide (P <0.001), indicating
that the uptake in these tissues was also at least partly αvβ3-mediated. This was similar for
the 68Ga- and 111In-labeled analogues. Kidney uptake of Al18F-NODAGA-E-[c(RGDfK)]2
(2.87 ± 0.96 %ID/g) was not blocked by an excess of non-radiolabeled RGD peptide (2.58
±0.40 %ID/g; P=0,094). Femur uptake of Al18F-NODAGA-E-[c(RGDfK)]2 was negligible,
indicating good in vivo stability of Al18F-NODAGA-E-[c(RGDfK)]2.
2.5. Micro-PET/CT and -SPECT/CT
Fused PET/CT (Figure 4A, C) and SPECT/CT (Figure 4E) scans show images that were in
line with the biodistribution data. On these scans, SK-RC-52 tumors were clearly visualized
with Al18F- and 68Ga-labeled NODAGA-E-[c(RGDfK)]2 and 111In-NODAGA-E-
[c(RGDfK)]2 respectively. The integrin αvβ3 specificity of all three radiolabeled
NODAGA-E-[c(RGDfK)]2 tracers in vivo was demonstrated in a blocking experiment where
the tracer was coinjected with an excess of nonradiolabeled NODAGA-E-[c(RGDfK)]2.
Addition of cold excess of NODAGA-E-[c(RGDfK)]2 resulted in decreased tumor
accumulation of the tracer compared to radiolabeled NODAGA-E-[c(RGDfK)]2 (Figures
4B, D and F). Al18F-, 68Ga- and 111In-NODAGA-E-[c(RGDfK)]2 also showed high
retention in the kidneys, from which could be deduced that Al18F was stably chelated by
NODAGA due to low uptake in the skeleton.
2.6. Discussion
In this study, we used the optimized Al18F-labeling method (27,28) for the radiofluorination
of NODAGA-E-[c(RGDfK)]2 and evaluated this radiotracer in in vitro and in vivo studies.
The in vitro and in vivo characteristics of this 18F-labeled dimeric RGD peptide were
directly compared with its 68Ga-and 111In-labeled counterparts.
Here, it was shown that Al18F-radiolabeled E-[c(RGDfK)]2 via NODAGA increased the
lipophilicity of the peptide. This was tested as it often leads to unfavorable characteristics in
vivo. However the degree of lipophilicity did not alter the preferred route of excretion,
which as determined from the biodistribution studies, was renal.
Using NODAGA allowed for the labeling of multiple isotopes and subsequent comparison
of images obtained from PET and SPECT. For the labeling with 68Ga (29) and 111In,
NODAGA was deemed a suitable chelator. However as shown in a study investigating the
use of different chelators, NODAGA turned out not to be an adequate chelator for Al18F
(30), although labeling efficiencies were similar to those found for Al18F-1,4,7-
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triazacyclononane-1,4,7-triacetic acid (NOTA)-PRGD2 (31). The relatively low
radiolabeling yields obtained with Al18F-NODAGA-E-[c(RGDfK)]2 might result from the
N3O3 donor set of NODAGA. This N3O3 donor set (hexadentate) provides a suitable
environment for the formation of highly stable aluminum chelates (32). However as the
coordination sphere of aluminum is saturated, access for fluorine was limited. D’Souza and
colleagues demonstrated that N3O2 donor set (pentadentate) ligands possess a single
coordination site for binding fluorine and thus might provide a more suitable chelator for all
three radionuclides, resulting in a more efficient Al18F-labeling procedure (33).
In a competitive binding assay using isolated integrin αvβ3 receptors, the IC50 values of the
NODAGA-conjugated and 1,4,7,10-tetra-azacylododecane-N,N’,N”,N”’-tetraaceticacid
(DOTA)-conjugated RGD peptide were determined to be within the subnanomolar range
and were not significantly different from each other. Recently, Knetsch and coworkers
compared the IC50 value of a NODAGA- and DOTA-conjugated RGD peptide (29). In their
study, the affinity of both tracers for αvβ3 integrin was also similar, showing that the
replacement of the DOTA chelator with the NODAGA chelator has no influence on binding
affinity and receptor-specific binding. It had already been demonstrated in previous studies
that DOTA-conjugation to a monomeric RGD peptide had no influence on the affinity for
integrin αvβ3 (34), which is in line with our observation that NODAGA-E-[c(RGDfK)]2 has
a similar affinity to integrin αvβ3 as the DOTA-conjugated analogue.
In the subcutaneous SK-RC-52 xenograft model, Al18F-NODAGA-E-[c(RGDfK)]2 showed
specific tumor uptake (3.44 ± 0.20 %ID/g) at 2 h p.i. and good in vivo stability. This has not
previously been determined for Al18F-labeled compounds via the NODAGA chelator.
Tumor uptake of this Al18F-labeled RGD peptide was significantly lower than that of
the 68Ga- and 111In-labeled analogs (5.78 ± 0.76 %ID/g and 4.99 ± 0.64 %ID/g,
respectively). Nonetheless, at 2 h p.i. the tumor/muscle ratio uptake of Al18F-NODAGA-E-
[c(RGDfK)]2 obtained here was at least as high as those reported by Liu et al. and Lang et
al. who determined the uptake of Al18F-NOTA-PRGD2 in integrin αvβ3-expressing U87MG
glioma tumor model (35,36). Whether the fast radiofluorination outweighs the relatively low
tumor uptake of Al18F-NODAGA-E-[c(RGDfK)]2 depends on the situation and
requirements for the use of a radiotracer in general. This study does however show that a
vector molecule can be radiofluorinated with Al18F via NODAGA in a quick fashion and
still maintain specific in vivo binding capabilities to its target.
Non-tumor tissues also showed specific uptake of Al18F-NODAGA-E-[c(RGDfK)]2,
suggesting integrin αvβ3 expression in these tissues. Indeed, β3 expression in colon,
pancreas and lung tissues has previously been described for rodents as well as for humans
(37). Al18F-labeled NODAGA-E-[c(RGDfK)]2 cleared rapidly from the blood, resulting in
high tumor-to-blood ratios at 2 h p.i., namely 120 ± 30.
The Al18F method is a fast (45 min) radiofluorination strategy that does not affect the
pharmacokinetics of the dimeric RGD peptide and the NODAGA chelator allows that the
peptide can be labeled with 68Ga and 111In too. The commonly used method for
efficient 18F-labeling of peptides consists of two steps: first the preparation of 18F-labeled
synthons (prosthetic groups), followed by subsequent conjugation to a peptide or protein. In
Dijkgraaf et al. Page 5
Contrast Media Mol Imaging. Author manuscript; available in PMC 2014 May 27.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
general, this fluorination is based on a nucleophilic substitution that requires time-
consuming azeotropic drying of the 18F-fluoride-kryptofix complex. The total synthesis and
formulation time for these methods ranges from 1 to 3 h. The Al18F-method used here
however is based on a chelator-derivatized peptide making this labeling method easy and
versatile.
3. CONCLUSIONS
The Al18F-method combines the ease of chelator-based radiolabeling methods with the
advantages of 18F, e.g., half-life, availability and low positron energy. The Al18F-labeled
NODAGA-E-[c(RGDfK)]2 could be synthesized in less than 45 min without the need for
azeotropic drying nor the need to synthesize a synthon. The results of the biodistribution
study of the Al18F-, 68Ga- and 111In-labeled NODAGA-E-[c(RGDfK)]2 peptide are
comparable, despite the low radiolabeling yield of Al18F-NODAGA-E-[c(RGDfK)]2, and
we hereby conclude that the Al18F-labeled NODAGA-E-[c(RGDfK)]2 peptide is a suitable
radiotracer for the non-invasive in vivo visualization of integrin αvβ3 expression in SK-
RC-52 xenografts.
4. EXPERIMENTAL
4.1. Synthesis of NODAGA-conjugated dimeric RGD peptide
NODAGA(tBu)3 (CheMatech, Dijon, France) was activated with O-(Benzotriazol-1-yl)-
N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) and the pH adjusted to >8
with diisopropulethylamine (DIPEA). Subsequently, the dimeric RGD peptide E-
[c(RGDfK)]2 (Peptides International, Inc., Louisville, KY, USA) was added and the reaction
was performed in dimethylformamide (DMF) at room temperature for at least 4.5 h. The
tBu-protecting groups were cleaved in 95% trifluoroacetic acid (TFA) for 5 h at room
temperature. NODAGA-E-[c(RGDfK)]2 was ultimately purified by RP-HPLC. The
structural formula of NODAGA-E-[c(RGDfK)]2 is shown in Figure 5.
4.2. Radiolabeling
18F labeling—NODAGA-E-[c(RGDfK)]2 was radiolabeled with 18F essentially as
described by Laverman et al (38). Briefly, a Chromafix cartridge with 2–6 GBq 18F (BV
Cyclotron VU, Amsterdam, The Netherlands) was washed with 3 mL of metal-free H2O. 18F
was eluted from the cartridge with 100 µL of 0.9% NaCl. Subsequently, 8.5 µL 2 mM AlCl3
in 0.1 M sodium acetate buffer (pH 4) per GBq of 18F was added to 18F. Finally, 80 µL of
this Al18F solution was added to 400 µL MeCN and 20 µL NODAGA-E-[c(RGDfK)]2 in 0.5
M sodium acetate (pH 4.1; 5 µg/µL). The reaction mixture was heated at 100 °C for 15 min.
The radiolabeled peptide was purified by RP-HPLC. Al18F-NODAGA-E-[c(RGDfK)]2-
containing fractions were collected and diluted 10-fold with H2O and purified on an Oasis®
HLB cartridge to remove acetonitrile and TFA. In brief, the fraction was applied on the
cartridge and the cartridge was washed with 3 × 1 mL H2O. The radiolabeled peptide was
then eluted with 500 µL 50% EtOH. Before injection into mice, the EtOH was evaporated at
95 °C and the peptide was diluted with 0.5% bovine serum albumin (BSA) in phosphate-
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buffered saline (PBS). Finally, 0.4 MBq (0.4 µg, 0.24 nmol) or 3–10 MBq (2.7–9.1 µg, 1.6–
5.5 nmol) was used per mouse for the biodistribution or imaging studies, respectively.
68Ga labeling—68Ga was obtained from an 1850 MBq 68Ge/68Ga generator (IGG-100,
Eckert & Ziegler, Berlin, Germany). The 68Ga was eluted with 0.1 M HCl (Ultrapure, J.T.
Baker, Deventer, The Netherlands) using an Econo Pump (Bio-Rad, Hercules, CA, USA) at
1 mL/min. Five 1 mL fractions were collected and an aliquot of the fraction containing the
highest activity was used for radiolabeling. 68Ga-labeled NODAGA-E-[c(RGDfK)]2 was
prepared by adding 40 µL of 2.5 M HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic
acid) to 10 µL of the peptide dissolved in 2.5 M HEPES (2 µg/µL). Then, 500 µL of
the 68Ga-eluate from the generator (200 MBq) was added. After 10 min at 100 °C, the 68Ga-
labeled peptide was purified on an Oasis® HLB 1 cc (10 mg) cartridge as described above.
Before injection into mice, the EtOH was evaporated at 95 °C and the peptide was diluted
with 0.5% BSA/PBS. Finally, 0.4 MBq (0.1 µg, 0.06 nmol) or 3–10 MBq (0.9–3 µg, 0.54–
1.8 nmol) was used per mouse for the biodistribution or imaging studies respectively.
111In labeling—For 111In-labeling, NODAGA-E-[c(RGDfK)]2 was dissolved 0.1 M 2-(N-
morpholino)ethanesulfonic acid, pH 5.5 (MES). Subsequently, 1–20 MBq 111InCl3
(Covidien, Petten, the Netherlands) per µg peptide was added. After 15 min at 100 °C,
the 111In-labeled peptide was further purified on an Oasis® HLB 1 cc (10 mg) cartridge as
described above. Before injection into mice, the EtOH was evaporated at 95 °C and the
peptide was diluted with 0.5% BSA/PBS. Finally, 0.4 MBq (0.3 µg, 0.18 nmol) or 10–20
MBq (0.5–0.8 µg, 0.24–0.48 nmol) was used per mouse for the biodistribution or imaging
studies, respectively.
HPLC analysis—Quality control was performed using RP-HPLC on a C-18 (Onyx
monolithic, 4.6 mm × 100 mm; Phenomenex) column. The column was eluted at a flow rate
of 3 mL/min with a gradient of 97% buffer A at 0–5 min and 80% buffer A to 75 % buffer A
at 5–20 min (buffer A, 0.1% v/v TFA in H2O; buffer B, 0.1% v/v TFA in acetonitrile). The
preparations were analyzed on an Agilent 1200 system (Agilent Technologies, Palo Alto,
CA, USA). Radioactivity was monitored using an in-line NaI radiodetector (Raytest GmbH,
Straubenhardt, Germany). Elution profiles were analyzed using Gina-star software (Raytest
GmbH, Straubenhardt, Germany). To obtain a radiochemical purity of >95%, Al18F-
NODAGA-E-[c(RGDfK)]2 was purified with the same HPLC system using the same
conditions.
4.3. Octanol/Water partition coefficient
To 0.5 mL of the radiolabeled peptide (1 kBq) in PBS, pH 7.4, 0.5 mL octanol was added.
After vigorous vortexing for 2 min at room temperature, the two layers were separated by
centrifugation (100 × g, 5 min). 100 εL samples were taken from each layer and
radioactivity was measured in a well-type gamma counter (Wallac Wizard 3”, Perkin-Elmer,
Waltham, MA). Log P values were calculated (n=3).
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4.4. Cell culture
SK-RC-52 human renal carcinoma cells, stably expressing integrin αvβ3, were cultured in
RPMI-1640 medium supplemented with 10% (v/v) fetal calf serum, 1% penicillin/
streptomycin and 1% glutamine (Invitrogen, Paisley, UK). Cells were maintained at 37 °C in
a humidified 5% CO2 atmosphere and routinely passaged using a 0.25% trypsin/EDTA
solution (Invitrogen).
4.5. Solid-phase αvβ3 integrin binding assay
The affinity of DOTA-E-[c(RGDfK)]2 and NODAGA-E-[c(RGDfK)]2 for integrin αvβ3
was determined using a solid-phase competitive binding assay as described previously (39).
Briefly, 111In-labeled DOTA-E-[c(RGDfK)]2 was prepared as described above at 5 MBq/
nmol. Plates coated with purified human integrin αvβ3 (150 ng/mL, Chemicon International,
Temecula, CA, USA) were blocked with 1% BSA in PBS, before incubation with 1 kBq
of 111In-DOTA-E-[c(RGDfK)]2 and appropriate dilutions (2×10−6 – 8×10−11 M) of
NODAGA-E-[c(RGDfK)]2 or DOTA-E-[c(RGDfK)]2 at 37°C for 1 h. The amount of bound
radioactivity was counted in a gamma counter. IC50 values of the E-[c(RGDfK)]2 peptides
were calculated by nonlinear regression using GraphPad Prism software (version 5.03 for
Windows). Each data point is the average of three determinations.
4.6. Biodistribution studies
In the right flank of 6- to 8-week-old female nude BALB/c mice, 2×106 SK-RC-52 cells in
200 µL medium was injected subcutaneously (s.c.). Two weeks after inoculation, when
tumor sizes ranged from 60–90 mm3 when measured by caliper, mice were injected
intravenously (i.v.) with the Al18F-, 68Ga- or 111In-labeled RGD peptide (0.4 MBq) in 200
µL 0.5% BSA in PBS. Mice were euthanized by CO2/O2 asphyxiation 2 h post-injection
(p.i.) (n=3–5). Blood, tumor and the major organs and tissues were dissected, weighed and
counted in a gamma counter. The percentage injected dose per gram (%ID/g) was
determined for each sample. The receptor-mediated localization of the radiolabeled peptide
was investigated by determining the biodistribution of the Al18F-, 68Ga- or 111In-labeled
peptide in the presence of an excess (100-fold) unlabeled peptide (n=3–5).
All animal experiments were approved by the local Animal Welfare Committee in
accordance with Dutch legislation and carried out in accordance to their guidelines.
4.7. microPET/CT and microSPECT/CT
In the right flank of 6- to 8-week-old female nude BALB/c mice, 2×106 SK-RC-52 cells in
200 µL medium was injected s.c.. Two weeks after inoculation, when tumor sizes ranged
from 60–90 mm3 when measured by caliper, mice were injected i.v. with 3–10 MBq
Al18F-, 68Ga- labeled NODAGA-E-[c(RGDfK)]2 or 12–20 MBq of 111In-NODAGA-E-
[c(RGDfK)]2. Cold excess NODAGA-E-[c(RGDfK)]2 (100-fold) was also injected. The
24.4 mmol/kg blocking dose of non-radiolabeled NODAGA-E-[c(RGDfK)]2 administered to
the control mice to acquire the PET/CT did not induce any side effects. One hour p.i., mice
were euthanized by CO2/O2 asphyxiation and scanned on either an animal PET/CT scanner
(Inveon®, Siemens Preclinical Solutions, Knoxville, TN, USA) with an intrinsic spatial
resolution of 2.5 mm (3) or the U-SPECT-II/CT (MILabs) (40). Mice were sacrificed prior
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to imaging, rather than imaged under anaethesia, to exclude movement artifacts as well as to
allow comparison of the SPECT/CT images with the biodistribution data. The animals were
then placed in a supine position in the scanner. Static PET or SPECT scans were acquired
over 45 m, followed by a CT scan for anatomical reference (PET: spatial resolution 113 µm,
80 kV, 500 µA, SPECT: spatial resolution 160 µm, 65 kV, 615 µA). PET/CT scans were
reconstructed using Inveon Acquisition Workplace software version 1.5 (Siemens
Preclinical Solutions, Knoxville, TN, USA), using an ordered set expectation
maximization-3D/maximum a posteriori (OSEM3D/MAP) algorithm with the following
parameters: matrix 256 × 256 × 159, pixel size 0.43 × 0.43 × 0.8 mm3 and a beta-value of
1.5. SPECT/CT scans were reconstructed with software from MILabs, using an ordered-
subset expectation maximization algorithm, with a voxel size of 0.375 mm.
4.8. Statistical analysis
All mean values are given as ± standard deviation (SD). Statistical analysis was performed
using a Welch's corrected unpaired Student t test or one-way ANOVA using GraphPad
InStat software (version 3.06; GraphPad Software).
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Figure 3.
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Figure 4.
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Figure 5.
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Table 1
Log P values of radiolabeled NODAGA-E-[c(RGDfK)]2 determined by octanol/water partition assays
Compound Log Poctanol/PBS ± SD
Al18F-NODAGA-RGD2 −4.26 ± 0.02
68Ga-NODAGA-RGD2 −4.50 ± 0.01
111In-NODAGA-RGD2 −4.34 ± 0.09
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